Deuterated Phenanthrene Tetraol in Smokers Who Are at High Risk For Lung Cancer

Study summary

This clinical trial studies deuterated phenanthrene tetraol in smokers who are at high risk for lung cancer. Studying samples of urine in the laboratory from smokers who are at high risk for lung cancer may help doctors learn more about biomarkers related to cancer.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studieddeuterated phenanthrene tetraol and pharmacological study

Plus 1 other study approaches.

Who it may be forLung Cancer · Squamous Lung Dysplasia

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 9, 2019 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?3 U.S. locations

Locations may change over time.

Who runs it?University of Minnesota

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: University of Minnesota
Interventions being studied: Drug: deuterated phenanthrene tetraol; Drug: pharmacological study; Drug: laboratory biomarker analysis

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Current or former smoker
18 years of age or older
Documentation of a diagnosis of no dysplasia, dysplasia, or metaplasia on bronchoscopy (white light and/or autofluorescence) conducted less than or equal to 10 years prior to registration
Not pregnant or breastfeeding
Able to provide written informed consent indicating an understanding of the nature of the study
Willing to comply with study requirements, including taking \[D10\]phenanthrene in water with 20% ethanol
No previous history of aerodigestive cancer
Not currently undergoing treatment for any cancers. Exception: basal cell or squamous cell skin cancer
Not currently taking any other investigational agents
No history of allergic reaction to \[D10\]phenanthrene or similar compounds
No major medical comorbidities, for example, renal dysfunction, heart function, and diabetes, to be adjudicated by study physicians
Not a former or recovering alcoholic
No use of metronidazole or antabuse less than or equal to 7 days prior to \[D10\]phenanthrene dosing, as they could potentially interact with ethanol

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Mayo ClinicRochester, Minnesota
Roswell Park Cancer InstituteBuffalo, New York
BC Cancer AgencyVancouver, British Columbia

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 9, 2019. Always confirm current availability with the study team.

View original record ↗